Product Description
Benzodepa is an aziridine alkylating agent that cross-links with DNA, causing inhibition of DNA synthesis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzodepa)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Atox Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Soft Tissue Infections|Sepsis|Wound Infection|Acute Kidney Injury|Communicable Diseases|Fournier Gangrene|Peritonitis|Fasciitis, Necrotizing
Phase 2: Communicable Diseases|Soft Tissue Infections
Phase 1: Shock, Septic|Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SA-AKI | P3 |
Terminated |
Wound Infection|Acute Kidney Injury|Soft Tissue Infections|Sepsis|Peritonitis |
2019-12-14 |
|
| ACCUTE | P3 |
Completed |
Soft Tissue Infections |
2019-10-18 |
|
| ACCUTE | P3 |
Completed |
Fournier Gangrene|Fasciitis, Necrotizing|Soft Tissue Infections|Communicable Diseases |
2019-08-18 |
|
| ATB-201 | P2 |
Completed |
Soft Tissue Infections|Communicable Diseases |
2012-09-01 |